IsoRay Inc represents a strong commitment to improving the lives of cancer patients through its innovative products and solutions. The company's corporate philosophy revolves around delivering cutting-edge brachytherapy solutions that offer precise, targeted cancer treatment. IsoRay Inc values integrity, quality, and teamwork, striving to provide physicians and patients with reliable and effective solutions for various cancer types. With its pioneering Cesium-131 brachytherapy seeds, IsoRay Inc aims to revolutionize cancer therapy by providing superior outcomes and enhancing patients' quality of life. The company's dedication to technological advancements and patient-centric approach sets it apart in the healthcare industry.

IsoRay Inc is primarily present in the United States.

IsoRay Inc has achieved several significant milestones. The company specializes in innovative brachytherapy solutions for the treatment of cancer. Over the years, IsoRay Inc has successfully developed and commercialized its proprietary Cesium-131 (Cs-131) brachytherapy seeds, which have been widely recognized for their effectiveness in treating prostate, brain, lung, and other cancers. IsoRay Inc has also obtained FDA clearance for its novel GammaTile® Therapy, a radiation treatment for brain tumors. Moreover, the company has expanded its global presence, establishing partnerships with healthcare providers and achieving regulatory approvals in multiple countries. These milestones highlight IsoRay Inc's dedication to improving cancer care through cutting-edge technologies and expanding its reach in the healthcare industry.

IsoRay Inc is a renowned company specializing in personalized internal radiation therapy products. Established in 1998, IsoRay has since become a prominent player in the medical industry. The company is dedicated to providing innovative solutions for cancer treatment, particularly in the field of brachytherapy. IsoRay Inc has developed and commercialized Cesium-131, a radiation isotope that offers superior treatment outcomes for various cancer types. With a steadfast commitment to improving patients' quality of life, IsoRay continues to lead the way in radiation therapy advancements. With its rich history and expertise, IsoRay Inc remains at the forefront of the fight against cancer.

Some of the main competitors of IsoRay Inc in the market include Varian Medical Systems, Eckert & Ziegler BEBIG, and Elekta AB.

IsoRay Inc is primarily active in the medical industry. With a focus on innovative advancements in brachytherapy, IsoRay Inc specializes in the production and sale of personalized cancer treatment solutions. This dynamic company operates within the healthcare sector, providing cutting-edge IsoRay Cesium-131 seed technology for the treatment of various forms of cancer. Through its industry expertise and dedication to improving patient outcomes, IsoRay Inc has gained recognition as a leading player in the medical field.

IsoRay Inc is a renowned company that specializes in the development and commercialization of innovative solutions for the treatment of cancer and other diseases. Its business model revolves around the research, production, and distribution of brachytherapy products. These products involve the use of radiation therapy, specifically Cesium-131, to target and destroy cancer cells while minimizing damage to healthy tissues. By offering safe and effective treatment options, IsoRay Inc aims to improve patient outcomes and enhance the quality of life for individuals battling cancer. With its focus on cutting-edge brachytherapy technologies, IsoRay Inc continues to advance the field of oncology and contribute to the fight against cancer.

P/E-talet för IsoRay är −9,53.

Det IsoRay KUV är 1,64.

AlleAktien Qualitätsscore för IsoRay är 6/10.

förväntade IsoRay omsättningen är 24,20 Mkr. USD.

förväntade IsoRay vinst är −4,17 Mkr. USD.

IsoRay Inc is a medical technology company based in Richland, Washington, USA. The company is the leading provider of innovative brachytherapy products. Brachytherapy is a method used in the treatment of cancer, where the radioactive source is directly placed into the cancer cells. IsoRay operates in two main business segments. The first segment focuses on the sale of Prostate Seed Implants. These implants are used in the treatment of prostate cancer and are IsoRay's flagship product. Implants provide better treatment by delivering a high dose of radiation directly to the cancer cells while protecting the surrounding organs and tissues. The implants consist of small radiation sources that are placed into the prostate. Brachytherapy is an alternative to other treatments such as surgery or radiation therapy. The implant is inserted by specially trained surgeons, and IsoRay provides support and training for medical personnel. IsoRay's second business segment focuses on the development and marketing of radioactive plaques and radiation sources. These products can be used in the treatment of brain cancer, lung cancer, and other types of cancer. The radioactive plaques are surgically implanted and deliver radiation directly to the tumor. The radiation sources are used in brachytherapy to ensure precise treatment. IsoRay has established itself as a market leader in brachytherapy products. The company aims to provide its customers with precise treatments while preserving the surrounding tissues and organs. The company collaborates closely with the medical community and research institutions to continually improve its products and technologies. IsoRay also has a number of patents that protect the effectiveness of its products and increase competitiveness. IsoRay operates an effective marketing and distribution program to make its products known in the medical community. The company works with healthcare facilities and offers training and support to ensure that its products are well understood and used. IsoRay also utilizes online marketing to create direct demand among patients and healthcare professionals. IsoRay's business model focuses on the development and marketing of brachytherapy products, particularly Prostate Seed Implants. The company is a market leader in this field and continues to strive to develop innovative technologies and provide precise, gentle treatments. The close collaboration with the medical community, the marketing and distribution initiatives, and the patent applications have helped the company grow in this lucrative market.

IsoRay delar ut en utdelning på 0 USD fördelad över utbetalningar per år.

Utbytet kan för närvarande inte beräknas för IsoRay eller så distribuerar bolaget inget utbyte.

ISIN för IsoRay är US46489V1044.

WKN för IsoRay är A0MQNM.

Ticker-symbolen för IsoRay är ISR.

Under de senaste 12 månaderna betalade IsoRay en utdelning på . Detta motsvarar en direktavkastning på ungefär . För de kommande 12 månaderna förväntas IsoRay betala en utdelning på 0 USD.

Aktiens direktavkastning för IsoRay är för närvarande .

IsoRay betalar ut dividenden kvartalsvis. Denna distribueras under månaderna .

IsoRay betalade utdelning varje år under de senaste 0 åren.

För de kommande 12 månaderna förväntas utdelningar uppgå till 0 USD. Detta motsvarar en utdelningsavkastning på 0 %.

IsoRay tilldelas sektorn 'Hälsa'.

För att få den senaste utdelningen från IsoRay den 2024-09-17 på 0 USD var du tvungen att ha aktien i ditt depå innan ex-dagen den 2024-09-17.

Utdelningen av den senaste dividenden skedde den 2024-09-17.

Under år 2023 delade IsoRay ut 0 USD i form av utdelningar.

Utdelningarna från IsoRay betalas ut i USD.